ID16927A - Suspensi berair dari ester asam lemak 9-hidroksirisperidon - Google Patents

Suspensi berair dari ester asam lemak 9-hidroksirisperidon

Info

Publication number
ID16927A
ID16927A IDP971649A ID971649A ID16927A ID 16927 A ID16927 A ID 16927A ID P971649 A IDP971649 A ID P971649A ID 971649 A ID971649 A ID 971649A ID 16927 A ID16927 A ID 16927A
Authority
ID
Indonesia
Prior art keywords
hydroxirirperperonone
suspension
water
fatty acid
fatty
Prior art date
Application number
IDP971649A
Other languages
English (en)
Indonesian (id)
Inventor
Marc Karel Josef Francois
Roger Carolus August Embrechts
Herman Karel Borghijs
Johan Monbaliu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID16927(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ID16927A publication Critical patent/ID16927A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IDP971649A 1996-05-20 1997-05-19 Suspensi berair dari ester asam lemak 9-hidroksirisperidon ID16927A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20

Publications (1)

Publication Number Publication Date
ID16927A true ID16927A (id) 1997-11-20

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP971649A ID16927A (id) 1996-05-20 1997-05-19 Suspensi berair dari ester asam lemak 9-hidroksirisperidon

Country Status (37)

Country Link
US (1) US6077843A (cs)
EP (1) EP0904081B1 (cs)
JP (1) JP3274687B2 (cs)
KR (1) KR100358373B1 (cs)
CN (1) CN1093762C (cs)
AR (1) AR007194A1 (cs)
AT (1) ATE208619T1 (cs)
AU (1) AU715572B2 (cs)
BG (1) BG62684B1 (cs)
BR (1) BR9706824B8 (cs)
CA (1) CA2236691C (cs)
CY (2) CY2270B1 (cs)
CZ (1) CZ291284B6 (cs)
DE (2) DE69708284T2 (cs)
DK (1) DK0904081T3 (cs)
EA (1) EA000536B1 (cs)
EE (1) EE03594B1 (cs)
ES (1) ES2167745T3 (cs)
FR (1) FR11C0035I2 (cs)
HR (1) HRP970276B1 (cs)
HU (2) HU224025B1 (cs)
ID (1) ID16927A (cs)
IL (1) IL124551A (cs)
LU (1) LU91842I2 (cs)
MX (1) MX9804816A (cs)
MY (1) MY126302A (cs)
NO (2) NO315931B1 (cs)
NZ (1) NZ330369A (cs)
PL (1) PL188309B1 (cs)
PT (1) PT904081E (cs)
SI (1) SI0904081T1 (cs)
SK (1) SK284013B6 (cs)
TR (1) TR199800923T2 (cs)
TW (1) TW487572B (cs)
UA (1) UA61898C2 (cs)
WO (1) WO1997044039A1 (cs)
ZA (1) ZA974331B (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ATE265846T1 (de) * 1998-02-25 2004-05-15 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
AU5489299A (en) * 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
EA200401009A1 (ru) 1999-03-31 2004-12-30 Янссен Фармацевтика Н.В. Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6750341B2 (en) * 2000-08-14 2004-06-15 Teva Pharmaceutical Industries Ltd. Preparation of risperidone
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
PT1539115E (pt) * 2002-07-29 2008-01-14 Alza Corp Métodos e formas de dosagem para libertação controlada de paliperidona
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
US8221778B2 (en) * 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
KR101242486B1 (ko) * 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006114384A1 (en) 2005-04-25 2006-11-02 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008128436A1 (en) * 2007-04-19 2008-10-30 Youxin Li Novel compounds for treatment of psychotic disorders, preparation methods and uses thereof
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
LT2234617T (lt) 2007-12-19 2021-05-25 Janssen Pharmaceutica Nv Dozės režimai, susiję su ilgo veikimo injekuojamais paliperidono esteriais
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
MX352189B (es) 2008-09-04 2017-11-10 Amylin Pharmaceuticals Llc Formulaciones de liberación sostenida usando portadores no acuosos.
PT2462246T (pt) 2009-09-28 2017-12-11 Intarcia Therapeutics Inc Estabelecimento rápido e/ou terminação de entrega de fármaco em estado estável substancial
CN102802631A (zh) 2009-10-30 2012-11-28 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012164582A1 (en) 2011-05-31 2012-12-06 Ramamohan Rao Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate.
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
SI3280416T1 (sl) 2015-04-07 2020-07-31 Janssen Pharmaceuticals, Inc. Režim odmerjanja pri izpuščenih odmerkih za estre paliperidona za vbrizgavanja z dolgotrajnim delovanjem
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
PL4005555T3 (pl) 2020-11-30 2024-09-02 Janssen Pharmaceutica Nv Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
SI4025188T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
KR20230116837A (ko) 2020-11-30 2023-08-04 얀센 파마슈티카 엔.브이. 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
LT4025189T (lt) 2020-11-30 2024-07-10 Janssen Pharmaceutica Nv Dozavimo režimai, susiję su prailginto atpalaidavimo paliperidono palmitato injekcinėmis vaisto formomis
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
KR20240049580A (ko) 2021-08-20 2024-04-16 얀센 파마슈티카 엔브이 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
AU694147B2 (en) * 1993-11-19 1998-07-16 Alkermes, Inc. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
AU684324B2 (en) * 1993-11-19 1997-12-11 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
PT833820E (pt) * 1995-06-06 2001-07-31 Aventis Pharmaceuticals Inc Av Derivados de benzisoxazol e indazol uteis como agentes antipsicoticos
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
BR9706824A (pt) 1999-03-23
US6077843A (en) 2000-06-20
CY2270B1 (en) 2003-07-04
HU224025B1 (hu) 2005-05-30
HK1017852A1 (en) 1999-12-03
TR199800923T2 (xx) 1999-09-21
CZ140198A3 (cs) 1999-04-14
CY2011011I2 (el) 2016-12-14
SI0904081T1 (en) 2002-04-30
CA2236691A1 (en) 1997-11-27
KR100358373B1 (ko) 2003-02-11
CN1093762C (zh) 2002-11-06
IL124551A0 (en) 1998-12-06
DK0904081T3 (da) 2002-02-25
NO981984D0 (no) 1998-04-30
NO315931B1 (no) 2003-11-17
ES2167745T3 (es) 2002-05-16
CZ291284B6 (cs) 2003-01-15
HRP970276B1 (en) 2002-04-30
HUP9901319A3 (en) 1999-11-29
JP2000513718A (ja) 2000-10-17
EA199800531A1 (ru) 1998-12-24
EE9800136A (et) 1998-10-15
AU2955997A (en) 1997-12-09
AR007194A1 (es) 1999-10-13
UA61898C2 (en) 2003-12-15
NZ330369A (en) 2000-04-28
PL327995A1 (en) 1999-01-04
WO1997044039A1 (en) 1997-11-27
IL124551A (en) 2001-08-26
HRP970276A2 (en) 1998-04-30
KR19990067603A (ko) 1999-08-25
SK62098A3 (en) 2000-04-10
NO981984L (no) 1998-11-19
NO2011015I2 (no) 2013-03-11
BG102443A (en) 1999-06-30
EP0904081B1 (en) 2001-11-14
ATE208619T1 (de) 2001-11-15
MY126302A (en) 2006-09-29
EA000536B1 (ru) 1999-10-28
PL188309B1 (pl) 2005-01-31
CA2236691C (en) 2007-01-02
EE03594B1 (et) 2002-02-15
DE69708284T2 (de) 2002-07-25
TW487572B (en) 2002-05-21
BR9706824B8 (pt) 2015-02-18
CY2011011I1 (el) 2016-12-14
BG62684B1 (bg) 2000-05-31
JP3274687B2 (ja) 2002-04-15
PT904081E (pt) 2002-04-29
MX9804816A (es) 1998-10-31
FR11C0035I2 (fr) 2013-08-16
CN1206347A (zh) 1999-01-27
DE69708284D1 (de) 2001-12-20
HUS1100013I1 (hu) 2017-03-28
EP0904081A1 (en) 1999-03-31
HUP9901319A2 (hu) 1999-08-30
LU91842I2 (fr) 2011-09-20
FR11C0035I1 (cs) 2011-07-10
NO2011015I1 (no) 2011-09-19
DE122011100027I1 (de) 2011-11-17
SK284013B6 (sk) 2004-08-03
ZA974331B (en) 1998-11-19
AU715572B2 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
ID16927A (id) Suspensi berair dari ester asam lemak 9-hidroksirisperidon
ID24981A (id) Suspensi berair dari ester-ester asam lemak 9-hidroksirisperidon submikron
ID15886A (id) Pembuatan alkil ester secara kontiniu dari asam met-akrilik
ID16433A (id) Penyediaan kontinyu alkil ester dari asam (met)akrilat
FI963867A7 (fi) Rasvahappoestereiden käyttö bioadhesiivisina aineina
ID18276A (id) Metoda pembuatan ester asam lemak
ID15885A (id) Pembuatan alkil ester secara kontiniu dari asam met-akrilik
PT823895E (pt) Esteres de acidos gordos como composto bioactivos
ID19514A (id) Penggunaan dari kondesasi asam formaldehid naftallenasulfat sebagai pembantu pengeringan
ID22095A (id) Asam aril-akrilat ester
ID27724A (id) Penstabil sediaan parmasi dari turunan-turunan asam gamma-aminobutira dan proses pembuatannya
ID26359A (id) Perbaikan proses untuk memperoleh kembali ksanthophil dari zat perekat tepung jagung
DE69922309D1 (de) Verfahren zur Herstellung von Fettsäureestern
ID17679A (id) Penggunaan dari kondensasi asam formaldehid naftalenasulfat sebagai pembantu pengeringan
ID21753A (id) Proses pembuatan asam asetat
DE69712890D1 (de) Herstellung von sorbitan-fettsäureestern als oberflächenaktive stoffe
DE69818500D1 (de) Herstellung von estern
DE59913680D1 (de) Fettsäurepartialester von Polyolen
ATE216359T1 (de) Sulfonsäureester von duftstoffen
DE69608883D1 (de) Neue verwendung von fettsäurealkylestern
EP0673914A3 (en) Preparation of alpha-keto acid esters.
ID17993A (id) Pembuatan alkil ester dari asam (meth) akrilik
FR2757165B1 (fr) Ester de l'acide maleimidobenzoique
ID22832A (id) Metode pembuatan asam formilfosfonat
ID20291A (id) Asam-asam oksobutirat tersubstitusi sebagai penghamba-penghambat matriks metaloproteasa